Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05100095 · ClinicalTrials.gov registry record · Phase 2
Hypofractionated Radiation Therapy for Merkel Cell Carcinoma
A Phase 2 study of Merkel Cell Carcinoma, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
- 1
- Study location
NCT05100095: Recruiting Phase 2 study of Merkel Cell Carcinoma, sponsored by M.D. Anderson Cancer Center.
NCT05100095 is a Phase 2 study of Merkel Cell Carcinoma that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 52 participants, roughly in line with the 49-participant average among 26 other Merkel Cell Carcinoma trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05100095, a Phase 2 study of Merkel Cell Carcinoma, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial tests whether hypofractionated radiation works to treat patients with Merkel cell carcinoma. Radiation therapy uses high energy radio waves to kill cancer cells and shrink tumors. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may be more convenient for patients and less immunosuppressive.
Conditions Studied
Interventions
- DRUG Radiation therapy
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2021-12-14 |
| Est. Completion | 2028-09-01 |
| Phase | Phase 2 |
What NCT05100095 shows while recruiting
NCT05100095 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, roughly in line with the 49-participant average among 26 other Merkel Cell Carcinoma trials with a reported enrollment target.
The record links to 1 condition, with Merkel Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Radiation therapy is the first listed.
NCT05100095 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT05100095 about?
NCT05100095 is a clinical study titled "Hypofractionated Radiation Therapy for Merkel Cell Carcinoma". This phase II trial tests whether hypofractionated radiation works to treat patients with Merkel cell carcinoma. Radiation therapy uses high energy radio waves to kill cancer cells and shrink tumors. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period ...
What is the current status of trial NCT05100095?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2021-12-14. Estimated completion is 2028-09-01.
What conditions does trial NCT05100095 study?
This clinical trial studies the following conditions: Merkel Cell Carcinoma.
What interventions are being tested in trial NCT05100095?
The interventions under investigation include: Radiation therapy (DRUG).
Who is sponsoring clinical trial NCT05100095?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05100095 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Merkel Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05100095's enrollment target sits among peer trials
52 9th of 26 higher than 18 of 26 other Merkel Cell Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Merkel Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TIL Therapy in cSCC and MCC
RECRUITING · Phase 2
-
Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma
RECRUITING · Phase 2
-
Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus
RECRUITING · Phase 2
-
EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers
RECRUITING · Phase 2
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
RECRUITING · Phase 2
-
Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI